Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) tinted gains of +2.5% (+0.13 points) to US$5.33. The volume of 0.1 Million shares climbed down over an trading activity of 113.74 Million shares. EPS ratio determined by looking at last 12 month figures is -2.06. Over the same time span, the stock marked US$7.45 as its best level and the lowest price reached was US$4.15. The corporation has a market cap of US$219.22 Million.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 27.6 percent. The return on equity ratio or ROE stands at -103.6 percent while most common profitability ratio return on investment (ROI) was -97.3 percent. The company’s institutional ownership is monitored at 53.3 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 99.6 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.8. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) is worth US$134.42 Million and has recently risen 2.47% to US$4.15. The latest exchange of 0.28 Million shares is below its average trading activity of 460.98 Million shares. The day began at US$0 but the price moved to US$4.15 at one point during the trading and finally capitulating to a session high of US$4.15. The stock tapped a 52-week high of US$6.45 while the mean 12-month price target for the shares is US$7.41.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 4.15, and a price to sales ratio of 10.18. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 13.9%. With an institutional ownership near 10.4%, it carries an earnings per share ratio of -0.59.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.